FEMY (Femasys) Interest Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FEMY Femasys Inc FEMY
56 GF Score
Price $3.05
GF Value $12.09
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Femasys Interest Received?

Interest Received only applicable to companies reporting Cash Flow from Operations in direct method.

FEMY
56GF Score
Femasys Inc FEMY
Interest Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Femasys (FEMY) Overvalued in 2026?

Based on GuruFocus' analysis, Femasys stock appears to be undervalued. The current stock price of $3.05 is trading 74.8% below its estimated GF Value™ of $12.09. GuruFocus considers Femasys to be Possible Value Trap.

Key valuation signals for FEMY:

  • Interest Received:
  • GF Value™: $12.09 vs. price of $3.05 (74.8% below fair value)
  • GF Score™: 56/100 with 7 warning signs

No single metric tells the full story. See the FEMY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Femasys Business Description

Address 3950 Johns Creek Court, Suite 100, Suwanee, GA, USA, 30024
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.
56GF Score

Get the complete analysis for FEMY

Interest Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.05
Price
$12.09
GF Value